SAB Biotherapeutics appoints Katie Ellias to Board of Directors, effective Nov 20, 2023

SAB Biotherapeutics, Inc.

Appointed Katie Ellias as Class II director, effective Nov 20, 2023, until 2026 annual meeting.
Ellias is Managing Director at JDRF T1D Fund (~$200M assets), which invested in SAB.
Board now has 10 directors, 8 independent.
Ellias brings T1D expertise; formerly at Endeavour Vision, Sofinnova Partners, Medtronic, McKinsey.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Helen Katherine Ellias

Class II Director

SABS · SAB Biotherapeutics, Inc.

Effective: 2023-11-20
Filed: November 20, 2023, 6:59 PM ET

recommended the appointment of, and the Board subsequently appointed, Ms. Helen Katherine Ellias to serve as a Class II director of the Company, effective as of November 20, 2023 until the Company’s 2026 annual meeting of stockholders

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Helen Katherine Ellias was appointed as Class II Director at SAB Biotherapeutics, Inc..

Action: appointed
Role: Class II Director

Exact text from the filing

recommended the appointment of, and the Board subsequently appointed, Ms. Helen Katherine Ellias to serve as a Class II director of the Company, effective as of November 20, 2023 until the Company’s 2026 annual meeting of stockholders

View on SEC.gov

SAB Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-065178

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.